1724 was inhibitory to cyclic AMP but not cyclic GMP-phosphodiesterase in brain extract.
1724 was inhibitory to cyclic AMP but not cyclic GMP-phosphodiesterase in brain extract.
When the skin adenyl cyclase was activated by AMP, the addition of theophyl line blocked this activation, but EG 626 or EG 467 further potentiated the activation.
These in vitro studies may serve as basic screening tests for the effectiveness of the specific phosphodiesterase inhibitors.
Amer et al. (1, 2) recently reported aberration of the cyclic nucleotide metabolism in aorta of hypertensive rats.
Regardless of the causes of the hypertension (spontaneous, stress-and desoxycorticosterone-induced) the common findings were the decreased level of cyclic AMP and the increased level of cyclic GMP. The decrease in cyclic AMP in aorta appeared to be due to the increased activity of low Km cyclic AMP-phosphodiesterase and also due to the decreased sensitivity of adenylate cyclase to 3-adrenergic agonist. Numano et al. have more recently found similar metabolic changes in aorta of rabbits fed a cholesterol rich diet (3) . Their findings suggest similar biochemical mechanism in atherogenesis.
If similar biochemical mechanisms are present in humans with hypertension, perhaps methods which increase cyclic AMP levels in the aorta may be therapeutically beneficial.
Although cyclic AMP levels can be elevated by stimulating adenylate cyclase in the aorta with a 19-adrenergic agonist, this may be hazardous since receptor sites for the agonist are already abnormal and weak in the diseased aorta. A practical way to control the cyclic AMP level in a tissue is the administration of an inhibitor for cyclic nucleotide-phosphodies terase, which inhibits the degradation of cyclic AMP.
We have compared the effectiveness of several inhibitors for the cyclic nucleotide-phosphodiesterase in various organs using an in vitro system. The determination of inhibition constants of these drugs will yield a practical parameter which could be used to select the most effective compound for clinical use. freshly prepared before each enzyme assay. Aorta, however, was obtained from albino rats and platelets were prepared fresh from human donors.
The enzyme assay system is similar to that described by Scott and Solomon ( to the Hank's medium causes cyclic AMP to accumulate in the skin slices (6) . Simultaneous addition of the phosphodiesterase inhibitors further potentiates the cyclic AMP accumu lation.
The cyclic AMP contents in the skin slices were measured by Gilman's binding protein method (7) with minor modifications (6).
RESULTS
Cyclic AMP phosphodiesterase Fig. I shows double reciprocal plots for the platelet enzyme. The phosphodiesterase from all tissues showed two Kms, high and low, similar to the platelet phosphodiesterase (Fig. 1) . The double reciprocal plots in the presence of theophylline are also shown in Table 1 . Inhibitor constants of these inhibitors were the smallest (the most effective) for papaverine and the largest (the least effective) for theophylline. The order of decreasing effectiveness on phosphodiesterase inhibitors was papaverine, EG 626, R020
1724, EG 467 and theophylline. This order was not changed in all tissues thus far tested.
Although there is no clear-cut tissue specificity of the inhibitors, it appears that both pa . EG 626, EG 467, and R020-1724 were dis solved in ethanol and then added to the reagent mixture.
The final ethanol con centration did not exceed 2
The effect of 2 % ethanol is also shown in this figure ([]) and the plots are the same as those of the control (x. ). All figures are the average of two experiments. Ki= x 10-s M; ( )*=Only approxi mation is listed, since a clear-cut linearity was not always obtainable. Effects of phosphodiesterase inhibitors on skin slices
In Table 3 , a preliminary experiment using skin slices is shown. When skin slices were incubated with epinephrine, the intracellular cyclic AMP levels were markedly increased.
The addition of phosphodiesterase inhibitors further potentiated this increase (Table 3) .
When the skin slices were incubated with 5'-AMP, the addition of theophylline blocked this activation, but EG 626 or EG 467 further potentiated the activation. Theophylline appears to block the AMP-receptor site on a cell membrane, hence it cannot be used as a phosphodies terase inhibitor, should AMP be one of natural activators of cyclic AMP in skin in vivo.
DISCUSSION
The clinical effectiveness of the phosphodiesterase inhibitors is influenced by several factors: 1. their potency as an inhibitor, 2. tissue specificity, 3. toxicity, 4. permeability and local retention at the site of action etc. The in vitro system used in the present study gave the first two parameters and should be a useful screening method prior to clinical testing.
The in vitro effectiveness is represented by the inhibition constant, i.e. the smaller the inhibitor constant, the better the clinical effectiveness. In this regard, both papaverine and EG 626 appear to be the most effective, but the former drug cannot be used clinically for any long-term therapy. EG 626, on the other hand, can be used without the problem of side effects (9). Shimamoto (10, 11) has treated certain atherosclerotic diseases with these inhibitors and observed that EG 626 gave much faster and better clinical response than did EG 467. These findings parallel their in vitro effectiveness.
Our data suggest that there is no clear-cut tissue specificity for the inhibitors. Their relative degree of in vitro effectiveness (Ki) is paralleled in different organs. For example, EG 467 is approx. twice as effective as theophylline in brain, heart, liver, etc. However, Kis of papaverine and EG 626 for platelets and arterial phosphodiesterase exhibited ex tremely small figures. Their Km/Ki ratio is 1-2 in platelets as compared with 5-1 in skin.
These drugs, therefore, can be effectively used as anti-platelet phosphodiesterase inhibitors.
Among the inhibitors tested, the in vitro effectiveness of theophylline, EG 467 and papaverine is the same for both cyclic AMP-and cyclic GMP-phosphodiesterase. Papaverine has the smallest Ki for both cyclic nucleotides. The relative effectiveness of EG 626 and R020-1724 toward cyclic AMP-phosphodiesterase is far better than that toward the cyclic GMP-specific enzyme. This is particularly so in platelets and brain in the case of EG 626 and specifically so in brain in the case of RO20-1724. The administration of these drugs should theoretically cause an increase in cyclic AMP level either in platelets and brain or in brain respectively, without greatly effecting the cyclic GMP level, and such may be of future clinical significance.
The solubility and permeability of an inhibitor are also important factors in determining their possible clinical usefulness. The in vitro data do not yield this information. A "semi" in vitro system to test these factors is possible. A tissue-slice model might be used to deter mine the increase in intracellular cyclic AMP potentiated by the addition of the inhibitor.
